ETIFOXINE & GRX-917 TIMELINE
Below is a timeline which illustrates the over 40 years of clinical data on etifoxine and the evolution of GRX-917.
September 2018
GRX-917 (Improved Etifoxine) Patent Issues
Researchers improved etifoxine using deuteration technology by reducing its dosing requirements. The US patent to the new and improved etifoxine issued on September 25, 2018.
May 2018
Compared etifoxine to lorazepam (Ativan®) – for alertness and cognitive functions in elderly patients
Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet
November 2015
Safety Profile of Etifoxine: A French Pharmacovigilance Survey
Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse or pharmacodependance were reported.
January 2015
Compared etifoxine to alprazolam (Xanax®) – for safety and efficacy
Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial Dan J. Stein
March 2009
French 2009 Study – Found it is Safe to Drive on Etifoxine
A French study in 2009 found that Etifoxine was safe to drive on, classify it as Level 1 for the purposes of driving a vehicle.
January 2006
Compared etifoxine to lorazepam (Ativan®) – established non-inferiority in adjustment disorder with anxiety ADWA
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin
April 2005
Researchers Discover Etifoxine Enhances Neurosteroids
French researchers discovered that etifoxine has a dual mechanism of action: A) it works at GABA channels, and B) it increases neurosteroids more effectively than any other known compound.